Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8959651 | 0.85 | EIF4A3 (0.54) | EIF4A3TNFRIPK1MEN1USP2 | |
| SCHEMBL29063065 | 0.84 | TNF (0.42) | EIF4A3TNFRIPK1HRH4MEN1 | |
| SCHEMBL8959558 | 0.83 | XDH (0.47) | EIF4A3TNFRIPK1ALOX15CDK1 | |
| SCHEMBL24740347 | 0.80 | ALOX15 (0.61) | EIF4A3HRH4ALOX15MEN1KMT2A | |
| SCHEMBL20853237 | 0.77 | TNF (0.39) | EIF4A3TNFRIPK1HRH4ALOX15 | |
| SCHEMBL10084620 | 0.77 | HRH4 (0.59) | EIF4A3HRH4MEN1USP2ALDH1A1 | |
| SCHEMBL25768432 | 0.76 | ALOX15 (0.47) | EIF4A3ALOX15MEN1ALDH1A1HPGD | |
| SCHEMBL25812181 | 0.73 | HRH4 (0.43) | EIF4A3HRH4MEN1ALDH1A1HPGD | |
| SCHEMBL27337665 | 0.73 | HRH4 (0.59) | HRH4MEN1USP2ALDH1A1HPGD | |
| SCHEMBL22198962 | 0.72 | TNF (0.43) | TNFRIPK1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | EIF4A3 582/4885TNF 4670/4885RIPK1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.